Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer, a new trial demonstrates.
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer, a new trial demonstrates.